NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.29 -0.01 (-2.29%) Closing price 04:10 PM EasternExtended Trading$0.29 +0.00 (+1.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About IGC Pharma Stock (NYSEAMERICAN:IGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.28▼$0.3050-Day Range$0.26▼$0.3552-Week Range$0.24▼$0.50Volume433,578 shsAverage Volume665,800 shsMarket Capitalization$28.63 millionP/E RatioN/ADividend YieldN/APrice Target$5.25Consensus RatingModerate Buy Company Overview IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. Read More IGC Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingIGC Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialIGC Pharma has a consensus price target of $5.25, representing about 1,735.7% upside from its current price of $0.29.Amount of Analyst CoverageIGC Pharma has only been the subject of 1 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for IGC Pharma are expected to remain at ($0.08) per share in the coming year.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.70% of the float of IGC Pharma has been sold short.Short Interest Ratio / Days to CoverIGC Pharma has a short interest ratio ("days to cover") of 2.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGC Pharma has recently increased by 11.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for IGC on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows2 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IGC Stock News HeadlinesIGC Pharma, Inc.: IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% EnrollmentMay 19, 2026 | finanznachrichten.deNew to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast, Stardust Power, Lost Soldier Oil and Gas ...May 16, 2026 | finanznachrichten.deSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.June 5 at 1:00 AM | Brownstone Research (Ad)Cannabis funding opensApril 30, 2026 | msn.comTLRY, CGC, IGC stocks light up on Trump pot reclassification hopes this weekApril 24, 2026 | msn.comIGC Pharma, Inc.: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionApril 22, 2026 | finanznachrichten.deIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionApril 22, 2026 | finance.yahoo.comIGC Pharma, Inc.: IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaApril 20, 2026 | finanznachrichten.deSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.2790 at the beginning of the year. Since then, IGC shares have increased by 2.5% and is now trading at $0.2860. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its earnings results on Tuesday, November, 12th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm earned $0.41 million during the quarter, compared to analyst estimates of $0.29 million. IGC Pharma had a negative net margin of 583.91% and a negative trailing twelve-month return on equity of 80.89%. Who are IGC Pharma's major shareholders? IGC Pharma's top institutional shareholders include Renaissance Technologies LLC (0.49%). View institutional ownership trends. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Alibaba Group (BABA), Tilray Brands (TLRY), Cronos Group (CRON), Micron Technology (MU) and Company Calendar Last Earnings11/12/2024Today6/05/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IGC's financial health is in the Yellow zone, according to TradeSmith. IGC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:IGC Previous SymbolNYSEMKT:IGC CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Price Target for IGC Pharma$5.25 High Price Target$5.25 Low Price Target$5.25 Potential Upside/Downside+1,735.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.12 million Net Margins-583.91% Pretax Margin-543.82% Return on Equity-80.89% Return on Assets-63.75% Debt Debt-to-Equity Ratio0.02 Current Ratio0.83 Quick Ratio0.53 Sales & Book Value Annual Sales$1.27 million Price / Sales22.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book3.58Miscellaneous Outstanding Shares100,090,000Free Float76,409,000Market Cap$28.63 million OptionableN/A Beta0.46 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSEAMERICAN:IGC) was last updated on 6/5/2026 by MarketBeat.com Staff. From Our Partners$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
